Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Is ATP7B a predictive marker in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy?

Katagiri H, Nakayama K, Rahman MT, Rahman M, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K.

Int J Gynecol Cancer. 2013 Jan;23(1):60-4. doi: 10.1097/IGC.0b013e318275afef.

PMID:
23221602
2.

Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.

Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T, Takenoshita S, Itoh K, Yaegashi N, Miyazaki K, Neamati N, Takebayashi Y.

Clin Cancer Res. 2004 Apr 15;10(8):2804-11.

3.

Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.

Miyashita H, Nitta Y, Mori S, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Kawamura H, Sato A, Morikawa H, Motegi K, Takebayashi Y.

Oral Oncol. 2003 Feb;39(2):157-62.

PMID:
12509969
4.

Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma.

Higashimoto M, Kanzaki A, Shimakawa T, Konno S, Naritaka Y, Nitta Y, Mori S, Shirata S, Yoshida A, Terada K, Sugiyama T, Ogawa K, Takebayashi Y.

Int J Mol Med. 2003 Mar;11(3):337-41.

PMID:
12579336
5.

Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma.

Aida T, Takebayashi Y, Shimizu T, Okamura C, Higasimoto M, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Miyazaki K, Ito K, Takenoshita S, Yaegashi N.

Gynecol Oncol. 2005 Apr;97(1):41-5.

PMID:
15790435
6.

Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.

Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Werner M, Lassmann S.

J Clin Pathol. 2012 Jan;65(1):29-35. doi: 10.1136/jclinpath-2011-200212. Epub 2011 Oct 19.

PMID:
22011448
7.

A seven-gene prognostic model for platinum-treated ovarian carcinomas.

Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E, Viens P, Birnbaum D, Bertucci F.

Br J Cancer. 2011 Jul 12;105(2):304-11. doi: 10.1038/bjc.2011.219. Epub 2011 Jun 7.

8.

Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy.

Woolston CM, Deen S, Al-Attar A, Shehata M, Chan SY, Martin SG.

Free Radic Biol Med. 2010 Nov 1;49(8):1263-72. doi: 10.1016/j.freeradbiomed.2010.07.008. Epub 2010 Jul 30.

PMID:
20650313
9.

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K.

Mod Pathol. 2012 Feb;25(2):282-8. doi: 10.1038/modpathol.2011.161. Epub 2011 Nov 18.

12.

Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma.

Ohbu M, Ogawa K, Konno S, Kanzaki A, Terada K, Sugiyama T, Takebayashi Y.

Cancer Lett. 2003 Jan 10;189(1):33-8.

PMID:
12445675
13.

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.

Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA.

Cancer. 2010 Mar 15;116(6):1462-8. doi: 10.1002/cncr.24915.

14.

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.

PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.

15.

ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl.

Xu W, Cai B, Chen JL, Li LX, Zhang JR, Sun YY, Wan XP.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):718-22. Epub 2007 Oct 18.

PMID:
17944925
16.

The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S.

Eur J Gynaecol Oncol. 2004;25(2):225-9.

PMID:
15032288
17.

Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.

Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, Song TJ, Kim MK, Kim TJ, Lee JW, Bae DS, Kim BG.

Gynecol Oncol. 2011 Aug;122(2):361-5. doi: 10.1016/j.ygyno.2011.04.025. Epub 2011 May 13.

PMID:
21570711
18.

Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.

Wrigley E, Verspaget HW, Jayson GC, McGown AT.

J Cancer Res Clin Oncol. 2000 Dec;126(12):717-21.

PMID:
11153145
19.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
20.

Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.

Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y.

Oncol Rep. 2001 Nov-Dec;8(6):1285-7.

PMID:
11605050

Supplemental Content

Support Center